Comparison of the levels of immunogenicity and safety of zostavax in adults 50 to 59 years old and in adults 60 years old or older

Clinical and Vaccine Immunology

Volumn 16, Issue 5, 2009, Pages 646-652

  Sutradhar, Santosh C ^a   Wang, William W B ^a   Schlienger, Katia ^a   Stek, Jon E ^a   Chan, Jin Xuivan S F ^a   Silber, Jeffrey L ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HERPES ZOSTER IMMUNOGLOBULIN; INFLUENZA VACCINE; PLACEBO; VARICELLA ZOSTER VACCINE;

ADULT; AGED; ANTIBODY RESPONSE; ANTIBODY TITER; AORTA VALVE STENOSIS; ARTICLE; BACKACHE; BASAL CELL CARCINOMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CONVULSION; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; GASTROENTERITIS; GROUPS BY AGE; HEADACHE; HEART ARRHYTHMIA; HEART INFARCTION; HERPES ZOSTER; HUMAN; IMMUNOGENICITY; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE SWELLING; INJECTION SITE WARMTH; LIMB FRACTURE; LUNG EDEMA; MAJOR CLINICAL STUDY; MALE; PNEUMONIA; PRIORITY JOURNAL; RESPIRATORY FAILURE; UPPER LIMB FRACTURE; UPPER RESPIRATORY TRACT INFECTION;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIBODIES, VIRAL; DOUBLE-BLIND METHOD; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HERPES ZOSTER VACCINE; HUMANS; MALE; MIDDLE AGED;

EID: 66849138602     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00407-08     Document Type: Article

References (32)

1. Brisson, M., and W. J. Edmunds. 2003. Epidemiology of varicella-zoster virus in England and Wales. J. Med. Virol. 70:S9-S14. "
2. Brisson, M., W. J. Edmunds, B. Law, N. J. Gay, R. Walld, M. Brownell, L.Roos, and G. De Serres. 2001. Epidemiology of varicella zoster virus infection in Canada and the United Kingdom. Epidemiol. Infect. 127:305-314.
3. Centers for Disease Control and Prevention. 2007. Recommended adult immunization schedule. MMWR Morb. Mortal. Wkly. Rep. 56(41):Q1-Q4. http://www.cdc.gov/mmwR/preview/mmwrhtml/mm5641-Immunizationa1.htm.
4. Chidiac, C., J. Bruxelle, J. P. Daures, T. Hoang-Xuan, P. Morel, A. Leplege, A. El Hasnaoui, and C. de Labareyre. 2001. Characteristics of patients with herpes zoster on presentation to practitioners in France. Clin. Infect. Dis. 33:62-69.
5. Czernichow, S., A. Dupuy, A. Flahault, and O. Chosidow. 2001. Herpes zoster: incidence study among "sentinel" general practitioners. Ann. Der-matol. Venereol. 128:497-501.
6. Diaz, C., P. Dentico, R. Gonzalez, R. G. Mendez, S. Cinquetti, J. L. Barben, A. Harmon, I. Chalikonda, J. G. Smith, J. E. Stek, A. Robertson, M. J. Caulfield, L. R. Biasio, J. L. Silber, C. Y. Chan, R. Vessey, J. Sadoff, I. S. Chan, H. Matthews, W. Wang, K. Schlienger, F. P. Schodel, and the Protocol 049 Study Group. 2006. Safety, tolerability, and immunogenicity of a two- dose regimen of high-titer varicella vaccine in subjects >13 years of age.Vaccine 24:6875-6885.
7. di Luzio Paparatti, U., F. Arpinelli, and G. Visona. 1999. Herpes zoster and its complications in Italy: an observational survey. J. Infect. 38:116-119.
8. Donahue, J. G., P. W. Choo, J. E. Manson, and R. Platt. 1995. The incidence of herpes zoster. Arch. Intern. Med. 155:1605-1609.
9. EMEA Committee for Medical Products for Human Use. 2009. Productinformation for ZOSTAVAX. EMEA, London, United Kingdom. http://www.emea.europa.eu/humandocs/PDFs/EPAR/zostavax/H-674-PI-en.pdf.
10. Gilderman, L. I., J. F. Lawless, T. M. Nolen, T. Sterling, R. Z. Rutledge, D. A. Fernsler, N. Azrolan, S. C. Sutradhar, W. W. Wang, I. S. Chan, K.Schlienger, F. Schoodel, J. L. Silber, and the Zostavax Protocol 010 StudyGroup. 2008. A double-blind, randomized, controlled, multicenter safety and immunogenicity study of a refrigerator-stable formulation of Zostavax. Clin. Vaccine Immunol. 15:314-319.
11. Gnann, J. W., and R. J. Whitley. 2002. Herpes zoster. N. Engl. J. Med. 347:340-346.
12. Hammond, O., Y. Wang, T. Green, J. Antonello, R. Kuhn, C. Motley, P.Stump, B. Rich, N. Chirmule, and R. D. Marchese. 2006. The optimization and validation of the glycoprotein ELISA assay for quantitative varicella-zoster virus (VZV) antibody detection. J. Med. Virol. 78:1679-1687.
13. Harpaz, R., I. R. Ortega-Sanchez, and J. F. Seward. 2008. Recommendations ofthe AdvisoryCommittee onImmunizationPractices: preventionofherpes zoster. Centers for Disease Control and Prevention, Atlanta, GA. http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5705a1.htm?s-cid=rr5705a1-e.
14. Hope-Simpson, R. E. 1975. Postherpetic neuralgia. J. R. Coll. Gen. Pract.25:571-575.
15. Insinga, R. P., R. F. Itzler, J. M. Pellisier, P. Saddier, and A. A. Nikas. 2005.The incidence of herpes zoster in a United States administrative database.J. Gen. Intern. Med. 20:748-753.
16. Kerzner, B., A. V. Murray, E. Cheng, R. Ifle, P. R. Harvey, M. Tomlinson,J. L. Barben, K. Rarrick, J. E. Stek, M. O. Chung, F. P. Schoodel, W. W.Wang, J. Xu, I. S. Chan, J. L. Silber, and K. Schlienger. 2007. Safety and immunogenicity profile of the concomitant administration of ZOSTAVAX and inactivated influenza vaccine in adults >50 years old. J. Am. Geriatr.Soc. 55:1499-1507.
17. Lange, J., S. K. Tyring, P. H. Peters, M. Nunez, G. Poland, M. Levin, C.Harper, I. Chalikonda, J. Li, J. G. Smith, M. J. Caulfield, I. S. F. Chan, K Schlienger, N. Azrolan, R. Vessey, J. L. Silber, and F. P. Schoodel. 2006.Immunogenicity, kinetics of VZV-specific CD4+ T-cell IFN-7 production and safety of a live attenuated Oka/Merck zoster vaccine in healthy adults >60 years of age, abstr. 857. Prog. Abstr. 44th Infect. Dis. Soc. Am. Annu. Conf., Toronto, Canada.
18. Law, B. J., D. Chateau, R. Walld, and L. L. Roos. 2004. Temporal trends in the annual population-based incidence of herpes zoster by age and gender: Manitoba, 1979-1998. Can. J. Infect. Dis. Med. Microbiol. 15:357-358.
19. Levin, M. J., M. N. Oxman, J. H. Zhang, G. R. Johnson, H. Stanley, A. R. Hayward, M. J. Caulfield, M. R. Irwin, J. G. Smith, J. Clair, I. S. Chan, H. Williams, R. Harbecke, R. Marchese, S. E. Straus, A. Gershon, A. Weinberg, and the Veterans Affairs Cooperative Studies Program Shingles Prevention Study Investigators. 2008. Varicella zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. J. Infect. Dis. 197:825-835.
20. Macaladad, N., T. Marcano, M. Guzman, J. Moya, F. Jurado, M. Thompson, C. Meechan, D. Li, K. Schlienger, I. Chan, J. Sadoff, F. Schodel, and J. L. Silber. 2007. Safety and immunogenicity of a zoster vaccine in varicella- zoster virus seronegative and low-seropositive healthy adults. Vaccine 25: 2139-2144.
21. Nichol, K. L., S. J. D'Heilly, M. E. Greenberg, and E. Ehlinger. 2009. Burden of influenza-like illness and effectiveness of influenza vaccination among working adults aged 50-64 years. Clin. Infect. Dis. 48:292-298.
22. Opstelten, W., J. W. Mauritz, N. J. de Wit, A. J. M. van Wijck, W. A. B. Stalman, and G. A. van Essen. 2002. Herpes zoster and postherpetic neuralgia: incidence and risk indicators using a general practice research database. Fam. Pract. 19:471-475.
23. Oxman, M. N., A. Weinberg, H. A. Stanley, G. R. Johnson, M. J. Levin, J. H. Zhang, M. Caulfield, A. R. Hayward, M. R. Irwin, I. S. F. Chan, J. Clair, J. Smith, and the Shingles Prevention Study Group. 2006. VZV-specific immune responses in older adult recipients of a clinically effective herpes zoster vaccine, abstr. PP193. Abstr. 4th Conf. Eur. Union Geriatr. Med. Soc., Geneva, Switzerland.
24. Oxman, M. N., M. J. Levin, G. R. Johnson, K. E. Schmader, S. E. Straus,L. D. Gelb, R. D. Arbeit, M. S. Simberkoff, A. A. Gershon, L. E. Davis, A. Weinberg, K. D. Boardman, H. M. Williams, J. H. Zhang, P. N. Peduzzi, C. E. Beisel, V. A. Morrison, J. C. Guatelli, P. A. Brooks, C. A. Kaufman, C. T. Pachucki, K. M. Neuzil, R. F. Betts, P. F. Wright, M. R. Griffin, P.Brunell, N. E. Soto, A. R. Marques, S. K. Keay, R. P. Goodman, D. J. Cotton, J. W. Gnann, J. Loutit, M. Holodniy, W. A. Keitel, G. E. Crawford, S. S. Yeh,Z. Lobo, J. F. Toney, R. N. Greenberg, P. M. Keller, R. Harbecke, A. R. Hayward, M. R. Irwin, T. C. Kyriakides, C. Y. Chan, I. S. Chan, W. W. Wang,P. W. Annunziato, J. L. Silber, and the Shingles Prevention Study Group.2005. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N. Engl. J. Med. 352:2271-2284.
25. Pellissier, J. M., M. Brisson, and M. J. Levin. 2007. Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Vaccine 25:8326-8337.
26. Schmader, K. 2001. Herpes zoster in older adults. Clin. Infect. Dis. 32:1481-1486.
27. Shapiro, E. D., A. T. Berg, R. Austrian, D. Schroeder, V. Parcells, A. Mar- golis, R. K. Adair, and J. D. Clemens. 1991. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N. Engl. J. Med. 325:1453-1460.
28. Straus, S. E., J. M. Ostrove, G. Inchauspe, J. M. Felser, A. Freifeld, K. D. Croen, and M. H. Sawyer. 1998. Varicella-zoster virus infections: biology, natural history, treatment, and prevention. Ann. Intern. Med. 108:221-237.
29. Tyring, S. K., F. Diaz-Mitoma, L. G. Padget, M. Nunez, G. Poland, W. M. Cassidy, N. D. Bundick, J. Li, I. S. Chan, J. E. Stek, P. W. Annunziato, and the Protocol 009StudyGroup. 2007. Safetyand tolerabilityofahigh-potency zoster vaccine in adults >50 years of age, Vaccine 25:1877-1883.
30. U.S. Food and Drug Administration. 2006. FDA licenses new vaccine to reduce older Americans' risk of shingles. U.S. Food and Drug Administration, Washington, DC. http://www.fda.gov/bbs/topics/NEWS/2006/NEW01378.html.
31. U.S. Food and Drug Administration. 2007. Advisory Committee background document on ZOSTAVAX. U.S. Food and Drug Administration, Washington, DC. http://www.fda.gov/ohrms/dockets/ac/05/briefin5-4198B2-3.pdf.
32. Watson, C. P. N., V. R. Watt, M. Chipman, N. Birkett, and R. J. Evans. 1991The prognosis with postherpetic neuralgia. Pain 46:195-199.